unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026

~ Narayana Health Date of submission: July 31, 2026 To, To, The Secretary The Secretary Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Mumbai – 400 051 Dalal Street, Mumbai – 400 001 Scrip Code – 539551 (EQ), 975516 & 976418 Scrip Code- NH Dear Sir/Madam, Sub: Outcome of the Board Meeting held on July 31, 2026 Pursuant to Regulation 30 read with Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 (“SEBI Listing Regulations”), this is to inform you that the Board of Directors of the Company at its meeting held today, i.e. July 31, 2026 (Friday) inter alia, has approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 together with the Limited Review Report reviewed by the Audit Committee and approved by the Board of Directors. A copy of the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 together with Limited Review Report is enclosed as Annexure for your information. The meeting of the Board of Directors commenced at 03:30 P.M. IST and ended at 06:00 P.M. IST. This is for your information and records. Thanking you Yours faithfully For Narayana Hrudayalaya Limited Sridhar S. Group Company Secretary, Legal & Compliance Officer Encl.: as above Narayana Hrudayalaya Limited Appointments CIN: L8511 0KA2000PLC027497 186-0208-0208 Registe red Office: 258/A, Bommasandra Industrial Area, Anekal Taluk, Bangalore 560099 Corporate Office: 261/A, 2nd Floor, Bommasandra Industrial Area, Anekal Taluk, Bangalore 560099 Tel +91 80 7122 2636 I Fax +91 80 2783 2648 I Email: info@narayanahealth.org I www.narayanahealth.org Deloitte Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Haskins & Sells LLP Bengaluru – 560 001 Karnataka, India Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF NARAYANA HRUDAYALAYA LIMITED 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of NARAYANA HRUDAYALAYA LIMITED (“the Company”), for the quarter ended June 30, 2026 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm’s Registration No. 117366W/W-100018) SA THY A Digitally signed by SA THY A PRAMOD PRAMOD KOUSHIK KOUSHIK Date: 2026.07.31 18:1S:58+05'30' Sathya P. Koushik Partner (Membership No. 206920) UDIN: 26206920AEJSKX6881 Place: Bengaluru Date: July 31, 2026 SPK/SG/TG/AB/2026 Regd. Office: 31st Floor, Tower 3, One International Center, Senapati Bapat Marg, Elphinstone Road (West), Mumbai – 400013 Narayana Hrudayalaya limited Registered office; No. 2S8/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru S60099, Karnataka, India Corporate office: 2nd Floor, No. 261/A, Bommasandra Industrial Ar.ea, Hosur Road, Bengaluru S60099, Karnataka, India CIN: L85110KA2000PLC027497, Website; www.narayanahealth.org, Email: investorrelations@narayanahealth.org STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (~ in million except per share data) Quarter ended Year Ended SI. 30-Jun-26 31-Mar-26 30-Jun-2S 31-Mar-26 Particulars No. (Unaudited) (Unaudited) (Unaudited) (Audited) Refer Note 5 1. Income (a) Revenue from operations 10,971.02 10,440.50 9,431.41 39,751.41 (bl Other income (refer note 4) 304.13 1,270.59 164.36 1,764.34 Total income 11,275.15 11,711.09 9,595.77 41,515.75 2. Expenses (a) Purchases of medical consumables, drugs, surgical Instruments and 2,599.81 2,389.86 2,211.31 9,134.03 other consumables (b) Changes in inventories of medical consumables, drugs, surgical (29.77) (10.45) 28.29 30.53 instruments and other consumables -(Increase)/ Decrease (c) Employee benefits expense 1,912.19 1,747.20 1,761.55 7,053.80 (d) Professional fees to doctors 2,201.89 2,239.38 1,935.62 8,189.31 (e) Other expenses 1,895.68 1,808.36 1,704.46 6,949.26 Expenses before depreciation and amortisation, finance costs and 8,579.80 8,174.35 7,641.23 31,356.93 e1eceptional items 3. Earnings before depreciation and amortisation, finance costs and 2,695.35 3,536.74 1,954.54 10,158.82 exceotlonal Items (1·2) (EBITDA) 4. Finance costs 336.66 387.82 306.23 1,271.16 5. Depreciation and amortisation expense 481.48 507.10 475.58 1,914.78 6. Total e•penses (2+4+5) 9,397.94 9,069.27 8,423.04 34,542.87 7. Profit before tax: and exceptional items (1-6} 1,877.21 2,641.82 1,172.73 6,972.88 8. Exceptional item (refer note 8) (452.76) 9. Profit before ta• (7+81 1,877.21 2,641.82 1,172.73 6,520.12 10. Tax expense (a) Current ta• -Current year 481.11 690.41 286.61 1,564.92 (b) Deferred tax charge/(credit) 17.55 (69.84) 12.41 (75.93) Total ta• e•oense 498.66 620.57 299.02 1,488.99 11. Net Profit for the period/ year (9-10) 1,378.55 2,021.25 873.71 5,031.13 12. Other comprehensh,e income Items that will not be reclassified subsequently to profit or loss (i) Re-measurement gains/(losses) on defined benefit plans (46.38) 20.84 (7.64) 9.45 (ii) Income ta• effect 11.67 (5.25) 1.92 (2.38) Items that will be reclassified subsequently to profit or loss (i) Effective portion of gains/ (losses) in cash flow hedge l.73 (6.90) (ii) Income tax effect (0.44) Other comprehensive income/(loss), net of taxes (34.71) 15.59 (4.43) 0.17 13. Total comprehensive income for the period/year (11+12) 1,343.84 2,036.84 869.28 5,031.30 14. Paid-up equity share capital (Face value of ~ 10 each) 2,043.61 2,043.61 2,043.61 2,043.61 15. Reserves (Other Equity) . 23,930.71 16. Earnings/ (loss) per share not annualis [Showing first 8,000 characters — download PDF for full document]